API | bardoxolone

bardoxolone Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Bardoxolone methyl is an experimental and orally-bioavailable semi-synthetic triterpenoid, based on the scaffold of the natural product oleanolic acid. Pre-clinical studies indicate that the compound acts as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway. A phase 3 clinical trial evaluating bardoxolone methyl for the treatment of chronic kidney disease (CKD) was terminated in October 2012 after patients treated with the drug were found to have experienced a higher rate of heart-related adverse events, including heart failure, hospitalizations, and deaths. ^Wikipedia

Chemistry

SMILES: CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@@]34C)C(=O)O
InChIKey: TXGZJQLMVSIZEI-UQMAOPSPSA-N
Mol. Mass: 491.67
ALogP: 6.29 Partition coefficient
ChEMBL Molecules:

bardoxolone

bardoxolone methyl

More Chemistry

Pharmacology

Mechanisms of Action:
- Inhibitor of nuclear factor kappa-B kinase subunit beta (Homo sapiens) ^UniProt
- Kelch-like ECH-associated protein 1 (Homo sapiens) ^UniProt
- Nuclear factor erythroid 2-related factor 2 (Homo sapiens) ^UniProt
- Peroxisome proliferator-activated receptor gamma (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (9)

Research & Development (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (29)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (29)

COVID-19 (Phase 2/Phase 3)

Cryptogenic Organizing Pneumonia (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 3)

Diabetic Nephropathies (Phase 3)

Dry Eye Syndromes (Phase 3)

Endocardial Fibroelastosis (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Glomerulosclerosis, Focal Segmental (Phase 2)

Hamman-Rich Syndrome (Phase 2)

Healthy Volunteers (Phase 1)

Hypertension, Pulmonary (Phase 3)

Idiopathic Interstitial Pneumonias (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Kidney Failure, Chronic (Phase 2)

Liver Diseases (Phase 1/Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Interstitial (Phase 2)

Lymphoma (Phase 1)

Melanoma (Phase 2)

Neoplasms (Phase 1)

Nephritis, Hereditary (Phase 3)

Obesity (Phase 1)

Pancreatic Neoplasms (Phase 1/Phase 2)

Pneumonia (Phase 2)

Polycystic Kidney, Autosomal Dominant (Phase 3)

Pulmonary Arterial Hypertension (Phase 2)

Renal Insufficiency, Chronic (Phase 3)

Sarcoidosis (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 36
# of Trial Organizations: 9

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue